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SUMMARY 
 Multiminicore disease is a recessive congenital myopathy characterized by the 
presence of small cores or areas lacking oxidative enzymes, in skeletal muscle fibres. 
From a clinical point of view, the condition is widely heterogeneous and at least four 
phenotypes have been identified; genetic analysis has revealed that most patients with the 
classical form of multiminicore characterized by rigidity of the spine, early onset and 
respiratory impairment harbour recessive mutations in the SEPN1 gene, whereas the 
majority of patients belonging to the other categories, including patients with 
ophthalmoplegia or patients with a phenotype similar to central core disease, carry 
recessive mutations in the RYR1. In the present review we discuss the most recent 
findings on the functional effect of mutations in SEPN1 and RYR1 and discuss how they 
may adversely affect muscle function and lead to the clinical phenotype.
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INTRODUCTION 
Multi-minicore disease (MmD; MIM # 255320) is an early onset congenital 
myopathy usually inherited in an autosomal recessive mode (1). Histochemical and 
electron microscopic studies on biopsies from patients affected by MmD show small 
cores, which are areas of sarcomeric disorganization lacking oxidative enzymes and 
mitochondria (fig. 1, panels C and D). Multiple small cores are present in most muscle 
fibres, affecting few sarcomeres and typically not running the length of the muscle fibre; 
this feature distinguishes MmD from central core disease (CCD) in which cores are larger 
and run the entire length of the fibre (fig.1 panels A and B). There are typically no signs 
of muscle regeneration/degeneration.  
Clinical features associated with the histopathologic appearance of multiminicores 
are markedly heterogeneous and to date four clinical phenotypes have been recognized. 
The “classic” and most common phenotype (2-4) is characterized by spinal rigidity, axial 
weakness, scoliosis and early respiratory impairment. In a second variant of MmD, in 
addition to a distribution of weakness and wasting similar to the classic form, patients 
also exhibit extraocular muscle involvement (2,5,6). In a third variant, patients show 
proximal weakness pronounced in the hip girdle similar to CCD with little or no 
respiratory impairment, whilst other patients may feature marked distal weakness, 
wasting and arthrogryposis (2,3). 
The clinical variability seen in MmD partially corresponds to underlying genetic 
heterogeneity: the first molecular defect identified in patients affected by the classical 
form of MmD, were mutations in the selenoprotein 1 (SEPN1) gene (4,7). Further genetic 
investigations revealed that patients affected by forms of MmD with ocular involvement, 
carried mutations in the skeletal muscle ryanodine receptor gene (RYR1) (8-10), as did 
those with predominant pelvic girdle weakness. The present review will focus on the 
molecular defects underlying MmD and in particular on recent advancements on the 
functional consequences of newly identified SEPN1 and RYR1 mutations. For more in-
depth clinical information, the readers are referred to several articles in this field (2,3,9). 
 
Mutations in the Selenoprotein N (SEPN1) gene: 
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 Selenium is an essential element whose deficiency can interfere with 
normal embryonic development and fertility. The major biological form of selenium in 
bacteria and eukaryotes is the 21st amino acid selenocysteine, which is found in the active 
site of selenoproteins and is directly involved in catalytic reactions (11). Selenocysteine 
is encoded by an in-frame UGA codon. In order to read through the UGA translational 
stop codon, the 3’-untranslated region of the selenoprotein mRNA must have a hairpin 
sequence called the selenocysteine insertion sequence (SECIS) which, together with a 
SECIS binding protein, a special elongation factor (EFsec) and a selenocysteyl-tRNA, 
form a functional complex. Disruption of this complex (or limiting selenium availability 
in the diet) results in premature termination at the UGA codon, giving rise to 
selenoprotein mRNAs which are susceptible to degradation via the “nonsense-mediated 
decay pathway” (12).  
At least 26 selenoproteins have been identified in humans and shown to mediate a 
number of important functions, including the regulation of thyroid hormone metabolism, 
maintenance of the redox status of the cell and scavenging reactive oxygen species 
(13,14). Selenoprotein N, one of the last members of selenoproteins to be identified, is a 
70 kDa integral membrane glycoprotein localized in the endoplasmic reticulum of many 
tissues, including pancreas, kidney, heart, liver, lung, brain and skeletal muscle. Though 
its function remains unknown, its expression is developmentally regulated as 
demonstrated by its reduced expression during human myoblast differentiation (15,16).  
SEPN1 is encoded by a gene (SEPN1; MIM#606210) present on human 
chromosome 1p36 (RSMD1 locus); SEPN1 is made up of 13 exons spanning 18.5 Kb 
giving rise to a transcript of 4.5 Kb encoding for a protein of 590 amino acids (17). Two 
isoforms are predicted to exist: isoform 1 corresponds to the full length transcript, 
whereas in isoform 2, exon 3 is spliced out. Mutations in the SEPN1 gene were first 
identified by Moghadaszadeh et al. (17) in 10 families whose members were affected by 
a congenital form of rigid spine muscular dystrophy (MIM #602771). In one of these 
families, the mutation (1385G->A) transformed the selenocysteine specific codon TGA 
into the stop codon TAA, thus preventing selenocysteine incorporation and leading to 
nonsense-mediated decay. In the other families, novel mostly private SEPN1 mutations 
were found. To date, approximately 20 mutations have been identified within the coding 
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sequence of the SEPN1 gene (Table 1)(4,18,19). Among these are a nonsense mutation 
(1370C->T), a homozygous 20 bp duplication in exon 1 and a 1 nucleotide insertion at 
position 1, that are all predicted to result in a truncated protein which should be degraded 
via the nonsense-mediated decay pathway. More recently, a point mutation within the 
SECIS domain of the hairpin-containing 3’ untranslated region of SEPN1 mRNA was 
found (20). The latter mutation, together with mutations affecting the initiation codon or 
insertions within exon 1, were shown to significantly diminish the level of SEPN1 
expressed in cultured fibroblasts (20), confirming that mRNA degradation occurs when 
the transcript is terminated prematurely or when the SECIS complex can not properly 
assemble and direct read-through the internal UGA selenocysteine –encoding, 
termination codon. 
It is noteworthy that at least half of the mutations identified in patients with the 
classical form of MmD give rise to truncated selenoprotein N. Thus, though the 
functional role of SEPN1 remains largely speculative, one can not exclude the possibility 
that the selenocysteine residues of SEPN1 might participate in redox reactions, as has 
been observed for other members of the selenoprotein family. If this is so, the lack of 
SEPN1 could be associated with alterations of redox activity of skeletal muscle 
membranes.  Behne et al. (13) reported the content of selenium in various rat tissues and 
organs and found that tissue containing most selenium appears to be the testes (6600 
µg/kg dry tissue), followed by liver, adrenal gland, pituitary gland and skeletal muscle 
(440 µg/kg dry tissue). If one considers that skeletal muscle represents approximately 
40% of the human body weight, then muscle is the body organ with the highest selenium 
content. But what is the role of selenium in skeletal muscle and how may truncation 
SEPN1 affect muscle function? And in particular, how can one link SENP1 deficiency to 
the multiminicores in skeletal muscles? One interesting observation is that patients with 
classical MmD share a very similar clinical phenotype, indicating that mutations in the 
SEPN1 gene result in a “all or nothing” effect. Selenium compounds have been shown to 
cause (i) calcium release from isolated rabbit sarcoplasmic reticulum vesicles and (ii) 
affect ryanodine binding in a biphasic manner, whereby low concentrations (high nM to 
sub- µM) open the RyR channel and high concentrations (100 µM), inhibit channel 
opening (21). The mechanism of action of selenium is thought to involve oxidation of 
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functional thiol groups on the RyR1 (21). Since the RyR1 contains 100 cysteine residues 
per monomer and their state of oxidation strongly influences channel activity (22), 
depletion of SEPN1 might be associated with an alteration of the SEPN1/selenium ratio 
which may result in a moderate oxidative stress leading to an abnormal function of the 
RyR calcium channel and/or of other integral SR proteins and even in those patients in 
whom SEPN1 mutations do not result in truncated proteins, the mutations may affect 
SEPN1-dependent redox activity. 
 
Mutations in the Ryanodine Receptor 1 (RYR1) gene:  
After the initial identification of SEPN1 mutations, it became clear that not all 
patients with MmD harbour such mutations and search for other candidate genes, 
revealed that some patients harbour mutations in the gene encoding the skeletal muscle 
ryanodine receptor (RYR1)(6,8,9). In the present review we will only focus on patients 
affected by myopathy with minicores not affected by the “classical” form of MmD. The 
mode of inheritance of this condition is usually autosomal recessive (whereas CCD is 
considered dominantly inherited), presence of multiple small cores in fibre types 1 and 2, 
which are short and do not run the fibre length and weakness of the hands.  
Ryanodine receptors (RyR) are intracellular channels mediating calcium release 
from intracellular stores of excitable cells (23). Three isoforms encoded by different 
genes have been identified at the molecular level: type 1 RyRs are predominantly 
expressed in skeletal muscle and in humans are encoded by a gene on chromosome 
19q13.1 (RYR1) (24). Type 2 RyRs are mainly expressed in the heart and cerebellum and 
are encoded by a gene present on human chromosome 1 (25). Type 3 RyRs are expressed 
throughout the central nervous system as well as in a variety of other tissues and their 
expression level appears to be developmentally regulated; the gene encoding RyR3 is 
located on human chromosome 15 (26). The three isoforms share an overall amino acid 
identity of approximately 60% and experimental evidence suggests that they are 
structurally similar, with a large hydrophilic NH2-terminal domain and a hydrophobic 
COOH-terminal domain containing several transmembrane domains as well as the 
channel pore.  
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RYR1 is composed of 106 exons and encodes for a protein of 5038 amino acids, 
which assembles as a tetramer of >2 MDa and constitutes the functional skeletal muscle 
sarcoplasmic reticulum calcium release channel (24,27), a key player in excitation-
contraction coupling i.e. the process linking plasma membrane depolarization to Ca2+ 
release from the lumen of the sarcoplasmic reticulum (28-30). In addition to the RyR 
protein, the functional channel binds a number of accessory proteins (calmodulin, S100, 
FK506BP, sorcin, homer, calcineurin , PKA) which regulate its activity (for review see 
31-32).  
More than 100 dominant mutations in the RYR1 have been identified to date in 
patients and found to associate with dominantly inherited conditions (for recent reviews 
see 33,34): Malignant Hyperthermia (MH; OMIM #145600) and Central Core Disease 
(CCD; OMIM # 117000). In these disorders, disease-causing mutations appear to cluster 
in 3 defined regions of the RYR1. In MH, a pharmacological disorder triggered by 
exposure to volatile anaesthetics and/or muscle relaxants (35,36), disease-linked 
mutations predominantly cluster in domains within the hydrophilic portion of the 
protomer, whereas in CCD most RYR1 substitutions occur in the hydrophobic pore-
forming region. As shown in Table 2, recessive RYR1 mutations identified so far in a 
subgroup of MmD patients, do not cluster in particular hot spots, but rather are 
distributed throughout the whole RYR1 gene. 
As to the functional effect of mutations in this protein, a number of studies have 
demonstrated that most RYR1 mutations associated with MH and CCD affect calcium 
homeostasis either because they render the channel hypersensitive to activation (MH-
linked mutations), or because they decrease the amount of calcium released after 
activation (CCD-linked mutations) (33,37). Few studies so far have appeared on the 
functional effect of recessive RYR1 mutations linked to minicore myopathies. In the first 
functional study (38,39) we showed that the P3527S and V4849I RYR1 substitutions are 
associated with a slightly elevated resting calcium concentration, but not depleted 
intracellular stores. Furthermore, upon pharmacological RyR1 activation, cells 
harbouring the homozygous P3527S mutation were found to release significantly less 
calcium. We hypothesised that since this mutation lies in the vicinity of calmodulin and 
S100 binding sites on the RyR1 and since the αhelix breaking amino acid proline is 
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substituted by serine, the mutation may interfere with the formation of a stable 
macromolecular complex, whereby proteins which normally bind to the RyR 
macromolecular complex and regulate its activity, do so in an altered way (38). A similar 
conclusion concerning instability of the RyR macromolecular complex carrying the 
S71Y+N2283H mutations was also recently reached (39), though in the latter case, (i) no 
reduction in calcium released was observed after pharmacological RyR stimulation, and 
(ii) one of the mutations (N2283H) actually increased the sensitivity of the RyR1 
activation by KCl and caffeine, and is probably also linked to the MHS phenotype. 
As to other MmD-linked RYR1 mutations, Western blot analysis on muscle 
biopsies from patients characterised by muscle weakness and ophthalmoplegia, carrying 
the R109W+M485V and the homozygous 14646+2.99 kb intronic splicing variant, 
revealed very low endogenous RyR protein levels (39,40). Thus, in some MmD patients, 
particularly those with ophthalmoplegia, part of the clinical phenotype may be caused by 
a decrease in the amount of calcium release channels present in the sarcoplasmic 
reticulum. In this case, depolarization of the plasma membrane will be accompanied by a 
reduction of calcium release not because the mutations affect the properties of the RyR 
channel per se or the intracellular stores, but simply because fewer channels are present. 
One aspect which remains to be investigated is whether ophthalmoplegia is due to a 
decrease in RyR1 content which can not be compensated by the expression of other RyR 
isoforms, such as RyR3; little is known about the expression of this isoform in the ocular 
rectus muscles. In a study on non-mammalian vertebrate RyR isoform expression, 
O’Brien et al. reported that extraocular muscles of fish and birds only express the αRyR 
isoform, whereas most other muscles such as the swimming muscles of fish or pectoral 
muscle of birds, express the α and ß RyR isoforms (41). Some adult skeletal muscles, 
including abdominal muscles, diaphragm and soleus have been shown to express type 3 
RyR (42). One plausible explanation for the partial muscle function in these MmD 
patients, is that in those muscles in which type 3 RyR is expressed, the latter isoform is 
functionally compensating for the diminished levels of RyR1, maybe by forming 
heteroduplex channels of RyR1and RyR3. Thus, the distinctive ocular involvement in 
this subset of patients may reflect the absence of compensation by type 3 RyR in the eye.  
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Finally, a recent in investigation aimed at uncovering novel mutations, has 
revealed yet another novel mechanism whereby apparently recessive RYR1 mutations 
may be causative of MmD. In a recent paper, Zhou et al. report that in a number of 
patients with recessive core myopathies (6/11), RYR1 is transcribed from only one allele 
in skeletal muscle and that the transcribed allele is usually paternally inherited and carries 
the mutation (43). Thus, such patients are heterozygous for the mutation at the genomic 
level, but only express the mutant allele in their skeletal muscles, mimicking a 
homozygous state (43); interestingly, silencing of the normal maternally inherited allele, 
is tissue specific and does not occur in B-cells which also express low levels of type 1 
RyR. One of the families where wild type allele silencing occurred carried the 
R109W+M485V substitutions. The M485V substitution did not affect the function of the 
RyR in a discernable way (39), whereas R109W expressed at the homozygous level (as 
found in the patient’s muscle), was accompanied by a significant decrease of ryanodine 
binding and inability to transport calcium. In addition, in this patient, the level of RyR 
detected in the muscle biopsy was very low (39). 
As more mutations are identified, it will be important to verify how often they are 
accompanied by a decrease in the RyR1 protein level and whether up-regulation of RyR3 
does indeed occur in the skeletal muscle of patients.  
 
CONCLUSIONS AND FUTURE OUTLOOKS 
 The identification of disease causing human mutations is of fundamental 
importance from a diagnostic point of view. For some diseases where accurate diagnosis 
will allow the patient to live a normal life by avoiding certain medications or foods and 
anticipation of severe complications such as respiratory insufficiency, the quality and 
duration of life have undoubtedly improved. For others however, the fact that they carry 
an identified mutation has little positive influence unless the defective gene or its gene 
product can be replaced by a wild type one. Advancing our understanding of the role of 
SEPN1 in muscle and whether its lack is indeed affecting the oxidised status of 
sarcoplasmic reticulum proteins, may help to develop pharmacological therapeutic 
strategies aimed at improving the quality of life of these patients. On the same line, 
reversal of gene silencing in the skeletal muscle of patients in which monoallelic 
 10 
expression leads to the expression of a mutated RYR1 gene, may similarly improve 
muscle function. Finally identifying how mutations affect the function of a protein is of 
fundamental importance if one needs to identify novel drugs which may partially reverse 
the negative effects of a mutation. 
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Figure 1: Histological features of muscle biopsies from patients carrying a mutation 
in the RYR1 gene (A and B) and in the SEPN1 gene (C and D). Hematoxylin and 
Eosin stain (H&E; A and C) and NADH-TR (B and D). 
